Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Astrazeneca Pharma India stock price, quote, forecast and news

ASTRAZEN.NS
INE203A01020

Price

7,340.65 INR
Today +/-
-2.01 INR
Today %
-2.53 %
P

Astrazeneca Pharma India stock price

INR
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Astrazeneca Pharma India stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Astrazeneca Pharma India stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Astrazeneca Pharma India stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Astrazeneca Pharma India's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Astrazeneca Pharma India Stock Price History

DateAstrazeneca Pharma India Price
9/26/20247,340.65 INR
9/25/20247,528.85 INR
9/24/20247,878.25 INR
9/23/20246,748.10 INR
9/20/20246,872.95 INR
9/19/20246,771.00 INR
9/18/20246,715.50 INR
9/17/20246,657.45 INR
9/16/20246,753.00 INR
9/13/20246,799.60 INR
9/12/20246,845.90 INR
9/11/20246,902.75 INR
9/10/20246,881.00 INR
9/9/20246,792.85 INR
9/6/20246,865.00 INR
9/5/20246,870.05 INR
9/4/20246,900.20 INR
9/3/20246,876.90 INR
9/2/20246,707.85 INR
8/30/20246,586.65 INR
8/29/20246,661.50 INR

Astrazeneca Pharma India Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Astrazeneca Pharma India, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Astrazeneca Pharma India from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Astrazeneca Pharma India’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Astrazeneca Pharma India. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Astrazeneca Pharma India’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Astrazeneca Pharma India’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Astrazeneca Pharma India’s growth potential.

Astrazeneca Pharma India Revenue, EBIT and net profit per share

DateAstrazeneca Pharma India RevenueAstrazeneca Pharma India EBITAstrazeneca Pharma India Net Income
202412.96 B INR1.71 B INR1.62 B INR
202310.03 B INR1.49 B INR992.9 M INR
20228.06 B INR693.6 M INR616 M INR
20218.14 B INR1.16 B INR933 M INR
20208.32 B INR1.03 B INR722.1 M INR
20197.28 B INR565.7 M INR544.5 M INR
20185.72 B INR345.4 M INR259.1 M INR
20175.49 B INR220.1 M INR200.5 M INR
20165.64 B INR-2.1 M INR52.6 M INR
20155.17 B INR-264.2 M INR-208.4 M INR
20144.74 B INR-225.6 M INR-5.1 M INR
20133.9 B INR-806.2 M INR-895.3 M INR
20125.32 B INR232.1 M INR197.7 M INR
20115.94 B INR948.8 M INR641.3 M INR
20093.97 B INR840.8 M INR576.2 M INR
20083.54 B INR1.06 B INR738.4 M INR
20073.04 B INR856.8 M INR614.6 M INR
20062.7 B INR675.8 M INR487.4 M INR
20052.25 B INR572.5 M INR430.6 M INR
20041.93 B INR401 M INR257.5 M INR

Astrazeneca Pharma India Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B INR)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B INR)EBIT (B INR)EBIT MARGIN (%)NET INCOME (B INR)NET INCOME GROWTH (%)DIV. (INR)DIV. GROWTH (%)SHARES (M)DOCUMENTS
199719981999200020012002200320042005200620072008200920112012201320142015201620172018201920202021202220232024
0.991.010.941.080.641.381.781.932.252.73.043.543.975.945.323.94.745.175.645.495.727.288.328.148.0610.0312.96
-2.22-6.8113.98-40.71115.6729.518.2516.8019.8012.5616.5912.0349.70-10.52-26.5521.399.099.03-2.684.2527.3314.23-2.20-0.9724.4929.18
63.7763.2856.1459.0163.7962.5065.8265.0666.5866.0668.5066.7766.4368.2862.1854.0060.1657.8360.5160.8659.2961.8458.8758.4654.6257.0447.66
0.630.640.530.640.410.861.171.261.51.782.082.372.644.063.312.112.852.993.413.343.394.54.94.764.45.726.17
0.140.130.160.180.020.140.370.40.570.680.861.060.840.950.23-0.81-0.23-0.26-00.220.350.571.031.160.691.491.71
14.3312.7316.4216.823.1310.3920.5920.7925.3925.0128.1829.8121.1715.964.37-20.65-4.75-5.11-0.044.016.037.7612.3214.238.6014.8413.23
0.110.10.140.140.020.10.250.260.430.490.610.740.580.640.2-0.9-0.01-0.210.050.20.260.540.720.930.620.991.62
--7.1431.733.65-84.51368.18143.692.3967.3213.2626.0820.20-21.9511.28-69.27-554.31-99.444,060.00-125.00284.6229.50110.0432.7229.22-33.9861.0462.80
---------------------------
---------------------------
252525252525252525252525252525252525252525252525252525
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Astrazeneca Pharma India Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Astrazeneca Pharma India is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B INR)RECEIVABLES (B INR)OTHER REC. (B INR)INVENTORIES (B INR)OTHER CURRENT LIAB. (M INR)CURRENT ASSETS (B INR)TANGIBLE ASSETS (B INR)LONG-T. INVEST. (M INR)LONG-T. REC. (M INR)INTANGIBLE ASSETS (M INR)GOODWILL (M INR)OTHER NON-CURRENT ASSETS (M INR)NON-CURRENT ASSETS (B INR)TOTAL ASSETS (B INR)LIABILITIESCOMMON STOCK (M INR)ADDITIONAL PAID-IN CAPITAL (M INR)RETAINED EARNINGS (B INR)OTHER EQUITY (M INR)UNREAL. GAINS/LOSSES (M INR)EQUITY (B INR)LIABILITIES (B INR)PROVISIONS (M INR)OTHER SHORT-TERM LIAB. (B INR)SHORT-TERM DEBTS (M INR)LONG-TERM DEBT PORTION (M INR)SHORT-TERM REC. (B INR)LONG-T. LIAB. (M INR)DEFERRED TAXES (M INR)OTHER LIAB. (M INR)LONG-T. LIABILITIES (M INR)DEBT (B INR)TOTAL CAPITAL (B INR)
199719981999200020012002200320042005200620072008200920112012201320142015201620172018201920202021202220232024
                                                     
0.050.090.140.110.260.270.30.710.671.081.110.730.660.830.520.170.880.240.771.151.261.732.533.524.4955.06
0.160.190.240.280.110.140.20.20.310.450.010.010.680.470.410.380.540.430.820.430.550.80.830.850.861.091.55
0.030.030.030.040.050.070.150.150.170.150.690.680.260.290.240.220.341.080.20.270.190.250.320.130.190.230.3
0.10.090.080.120.260.430.480.260.250.340.240.340.350.570.750.850.960.860.780.591.141.191.661.61.411.912.29
0.60.60.71.71.210.725.410.232.336.865.480159.535.125.129.829.821.184.672.372.174.48384108.6119.1130.7
0.340.40.490.550.670.931.171.341.432.062.112.562.012.21.951.652.752.632.662.523.214.055.426.197.068.359.33
0.20.190.210.240.240.240.260.290.310.310.310.290.270.510.90.981.041.131.040.920.790.820.960.850.770.70.65
33.942.265.662.610.60.60.60.60.10.10.10.10.10.10.10.1000.10000029.3310
0000000000000236.5351.4306.9370.6345.5319.8316.5277.7517.4536.2564.3549.7554.4546.5
00000000024.918.912.930.1000000000000021.1
000000000000000000000000000
00003.30.604.645.741.94948.749.9140.9250123.53.75.9472.4406.4328.2236.1146.5145.4163206.7237.2
0.230.240.280.30.250.240.260.30.360.370.380.350.350.891.51.411.411.481.831.641.41.571.641.561.511.491.45
0.570.630.770.860.931.171.431.631.792.432.492.912.363.093.453.064.164.124.494.154.615.627.067.758.579.8510.78
                                                     
505050505050505050505050505050505050505050505050505050
000000000000000000000000000
0.320.410.530.620.620.710.930.911.221.371.541.111.41.751.840.951.671.461.972.162.42.943.584.55.045.817.04
00000000000000000012.716.520.82115.915.919.525.732.9
000000000000000000000000000
0.370.460.580.670.670.760.980.961.271.421.591.161.451.81.8911.721.512.032.232.473.013.644.565.115.897.12
0000000000000.120.140.210.911.11.111.330.880.951.682.11.781.882.281.97
000000000063.7112.442.8218.5705.3645.4143.6136.8389.8369.3414.2512.6652.3636.5668.2519.8552.3
0.150.140.20.20.220.410.440.680.480.980.80.990.720.790.610.51.191.340.720.660.70.40.50.580.741.011.04
00000000000099830.34.22.88.8000000000
000000000000000000000025.435.136.135.218.1
0.150.140.20.20.220.410.440.680.480.980.871.10.891.251.552.062.442.62.431.92.072.593.273.033.333.843.57
44.229.700000000062500000000009386.350.236.927.8
000028.92.55.9033.432.131.82520.500000000000000
00-4.5-6.300000000036.25.44.94.910.221.622.866.620.253.864.17585.662.1
44.229.7-4.5-6.328.92.55.9033.432.131.865020.536.25.44.94.910.221.622.866.620.2146.8150.4125.2122.589.9
0.20.170.190.190.250.410.450.680.521.010.91.750.911.291.562.062.442.612.451.932.142.613.423.193.453.963.66
0.570.630.770.860.931.171.431.631.792.432.492.912.363.093.453.064.164.124.494.154.615.627.067.758.579.8510.78
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Astrazeneca Pharma India provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Astrazeneca Pharma India's financial health and stability.

Assets

Astrazeneca Pharma India's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Astrazeneca Pharma India must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Astrazeneca Pharma India after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Astrazeneca Pharma India's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B INR)DEPRECIATION (M INR)DEFERRED TAXES (M INR)CHANGES IN WORKING CAPITAL (M INR)NON-CASH ITEM (M INR)PAID INTEREST (M INR)PAID TAXES (M INR)NET CASH FLOW FROM OPERATING ACTIVITIES (B INR)CAPITAL EXPENDITURES (M INR)CASH FLOW FROM INVESTING ACTIVITIES (B INR)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B INR)INTEREST INCOME AND EXPENSES (M INR)NET DEBT CHANGE (M INR)NET CHANGE IN EQUITY (M INR)CASH FLOW FROM FINANCING ACTIVITIES (M INR)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M INR)TOTAL DIVIDENDS PAID (M INR)NET CHANGE IN CASH FLOW (B INR)FREE CASH FLOW (M INR)SHARE-BASED COMPENSATION (M INR)
19971998199920002001200220032004200520062007200820092011201220132014201520162017201820192020202120222023
0.180.170.210.220.050.170.380.440.650.750.951.140.881.010.29-0.70-0.210.060.360.440.731.141.270.831.34
424445423348464451575868608873122101152174158147149185201169162
00000000000000000000000000
-98-82-77-20068-143-31432-360-207-527-342-590-39576614100-334391-120-384-253-363-36581-710
-18-23-51-1-7-16-18-20-58-53-87-54-29-57-55-94-209-67-53-12-113-73-88-59-72-210
0000000000000000000000111096
616658942888153145231271362326356446308-27682911741351336325247408
0.10.110.120.060.150.060.10.490.280.550.40.820.330.650.39-0.06-0.01-0.460.570.380.090.550.871.051.010.58
-55-48-55-68-39-56-65-81-77-75-68-48-71-322-398-187-216-238-90-56-62-186-142-77-96-85
-0.06-0.05-0.04-0.070.02-0.03-0.05-0.06-0.04-0.02-0.030.050.02-0.28-0.34-0.16-0.15-0.19-0.040-0.090.04-1.711.730.050.18
-000.02-00.060.030.020.020.040.050.040.10.090.050.060.030.070.050.050.06-0.030.23-1.571.810.140.27
00000000000000000000000000
-22-22-35000000000-62100000-2000-22-28-35-38
00000000000000000000000000
-20-22-37-15-19-15-20-22-280-113-339-541-1,108-290-290-1038620-5000-63-89-94-244
151513500-2-2-32-14-42-170-113-41-40-148620-2000-16-10-9-6
-13-16-15-20-19-15-18-19-247-99-297-371-373-249-249-89000000-25-50-50-200
0.020.040.05-0.030.150.010.030.41-0.040.410.030.33-0.760.08-0.24-0.320.71-0.640.530.38-0.010.59-0.92.690.960.52
45.357.269-8.3105.9-0.233.3411.9203471.2328.7768.2254.5322.3-11.1-248.3-224.4-695.1479.5324.525.1362.9732970.7911.8497.7
00000000000000000000000000

Astrazeneca Pharma India stock margins

The Astrazeneca Pharma India margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Astrazeneca Pharma India. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Astrazeneca Pharma India.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Astrazeneca Pharma India's sales revenue. A higher gross margin percentage indicates that the Astrazeneca Pharma India retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Astrazeneca Pharma India's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Astrazeneca Pharma India's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Astrazeneca Pharma India's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Astrazeneca Pharma India. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Astrazeneca Pharma India's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Astrazeneca Pharma India Margin History

Astrazeneca Pharma India Gross marginAstrazeneca Pharma India Profit marginAstrazeneca Pharma India EBIT marginAstrazeneca Pharma India Profit margin
202447.66 %13.23 %12.47 %
202357.05 %14.84 %9.9 %
202254.62 %8.61 %7.65 %
202158.47 %14.24 %11.47 %
202058.87 %12.33 %8.68 %
201961.84 %7.77 %7.48 %
201859.29 %6.04 %4.53 %
201760.86 %4.01 %3.65 %
201660.51 %-0.04 %0.93 %
201557.84 %-5.11 %-4.03 %
201460.16 %-4.76 %-0.11 %
201354.01 %-20.65 %-22.93 %
201262.19 %4.37 %3.72 %
201168.29 %15.97 %10.8 %
200966.44 %21.19 %14.52 %
200866.78 %29.83 %20.84 %
200768.49 %28.2 %20.23 %
200666.06 %25.03 %18.05 %
200566.59 %25.4 %19.11 %
200465.07 %20.78 %13.35 %

Astrazeneca Pharma India Stock Sales Revenue, EBIT, Earnings per Share

The Astrazeneca Pharma India earnings per share therefore indicates how much revenue Astrazeneca Pharma India has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Astrazeneca Pharma India earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Astrazeneca Pharma India's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Astrazeneca Pharma India’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Astrazeneca Pharma India's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Astrazeneca Pharma India Revenue, EBIT and net profit per share

DateAstrazeneca Pharma India Sales per ShareAstrazeneca Pharma India EBIT per shareAstrazeneca Pharma India Earnings per Share
2024518.21 INR68.57 INR64.6 INR
2023401.19 INR59.54 INR39.72 INR
2022322.24 INR27.74 INR24.64 INR
2021325.42 INR46.35 INR37.32 INR
2020332.72 INR41.02 INR28.88 INR
2019291.32 INR22.63 INR21.78 INR
2018228.8 INR13.82 INR10.36 INR
2017219.46 INR8.8 INR8.02 INR
2016225.49 INR-0.08 INR2.1 INR
2015206.83 INR-10.57 INR-8.34 INR
2014189.59 INR-9.02 INR-0.2 INR
2013156.17 INR-32.25 INR-35.81 INR
2012212.61 INR9.28 INR7.91 INR
2011237.61 INR37.95 INR25.65 INR
2009158.72 INR33.63 INR23.05 INR
2008141.7 INR42.26 INR29.54 INR
2007121.54 INR34.27 INR24.58 INR
2006108 INR27.03 INR19.5 INR
200590.14 INR22.9 INR17.22 INR
200477.17 INR16.04 INR10.3 INR

Astrazeneca Pharma India business model

Astrazeneca Pharma India is one of the most popular companies on Eulerpool.com.

Astrazeneca Pharma India Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Astrazeneca Pharma India historical P/E ratio, EBIT, and P/S ratio.

Astrazeneca Pharma India shares outstanding

The number of shares was Astrazeneca Pharma India in 2023 — This indicates how many shares 25 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Astrazeneca Pharma India earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Astrazeneca Pharma India's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Astrazeneca Pharma India’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Astrazeneca Pharma India's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Astrazeneca Pharma India Stock splits

In Astrazeneca Pharma India's history, there have been no stock splits.

Astrazeneca Pharma India dividend history and estimates

In 2023, Astrazeneca Pharma India paid a dividend amounting to 16 INR. Dividend means that Astrazeneca Pharma India distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Astrazeneca Pharma India provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Astrazeneca Pharma India’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Astrazeneca Pharma India's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Astrazeneca Pharma India Dividend History

DateAstrazeneca Pharma India Dividend
202424 INR
202316 INR
20228 INR
20212 INR
20202 INR
20191 INR
20123.5 INR
201110 INR
200915 INR
200815 INR
200712 INR
20064 INR
20059.16 INR
20040.78 INR

Astrazeneca Pharma India dividend payout ratio

In 2023, Astrazeneca Pharma India had a payout ratio of 14.92%. The payout ratio indicates the percentage of the company's profits that Astrazeneca Pharma India distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Astrazeneca Pharma India represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Astrazeneca Pharma India could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Astrazeneca Pharma India's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Astrazeneca Pharma India Payout Ratio History

DateAstrazeneca Pharma India Payout ratio
202417.58 %
202314.92 %
202232.47 %
20215.36 %
20206.93 %
20194.59 %
201814.92 %
201714.92 %
201614.92 %
201514.92 %
201414.92 %
201314.92 %
201244.25 %
201138.99 %
200965.08 %
200850.8 %
200748.82 %
200620.52 %
200553.19 %
20047.57 %
Unfortunately, there are currently no price targets and forecasts available for Astrazeneca Pharma India.

Astrazeneca Pharma India latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20205.31 INR7.45 INR (40.17 %)2021 Q1
3/31/20208.54 INR3.83 INR (-55.15 %)2020 Q4
1

Eulerpool ESG Scorecard© for the Astrazeneca Pharma India stock

Eulerpool World ESG Rating (EESG©)

81/ 100

🌱 Environment

99

👫 Social

78

🏛️ Governance

67

Environment

Scope 1 - Direct Emissions
618
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
618
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees16.051
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Astrazeneca Pharma India list of shareholders

%
Name
Stocks
Change
Date
75.00000 % AstraZeneca PLC18,750,00003/31/2024
2.88102 % Nippon Life India Asset Management Limited720,25576,5393/31/2024
2.71631 % Trivedi (Tejas B)679,078012/31/2023
2.71631 % Trivedi (Tejas Bhalchandra)679,078679,0783/31/2024
2.43454 % Trivedi (Shivani Tejas)608,636608,6363/31/2024
2.43454 % Trivedi (Shivani T)608,636012/31/2023
1.84288 % Trivedi (Minaxi Bhalchandra)460,72003/31/2024
0.79536 % The Vanguard Group, Inc.198,839-5613/31/2024
0.45358 % ICICI Prudential Asset Management Co. Ltd.113,39676,5962/29/2024
0.43123 % Investor Education Protection Fund107,807-12512/31/2023
1
2
3
4

Astrazeneca Pharma India Executives and Management Board

Mr. Sanjeev Panchal
Astrazeneca Pharma India Managing Director, Executive Director (since 2023)
Compensation 5.79 M INR
Mr. Narayan Seshadri66
Astrazeneca Pharma India Non-Executive Independent Chairman of the Board
Compensation 1.4 M INR
Ms. Shilpa Divekar49
Astrazeneca Pharma India Non-Executive Independent Director
Compensation 1.3 M INR
Ms. Revathy Ashok64
Astrazeneca Pharma India Non-Executive Independent Director
Compensation 1.2 M INR
Mrs. Bhavana Agrawal
Astrazeneca Pharma India Chief Financial Officer, Additional Director and Whole-time Director (since 2023)
1
2

Most common questions regarding Astrazeneca Pharma India

What is the P/E ratio of Astrazeneca Pharma India 2024?

The Astrazeneca Pharma India P/E ratio is 113.63.

What is the P/S ratio of Astrazeneca Pharma India 2024?

The Astrazeneca Pharma India P/S ratio is 14.17.

What is the AlleAktien quality score of Astrazeneca Pharma India?

The AlleAktien quality score for Astrazeneca Pharma India is 7/10.

What is the revenue of Astrazeneca Pharma India 2024?

The Astrazeneca Pharma India revenue is 12.96 B INR.

How high is the profit of Astrazeneca Pharma India 2024?

The Astrazeneca Pharma India profit is 1.62 B INR.

What is the business model of Astrazeneca Pharma India

No history available for Astrazeneca Pharma India.

What is the Astrazeneca Pharma India dividend?

Astrazeneca Pharma India pays a dividend of 8 INR distributed over payouts per year.

How often does Astrazeneca Pharma India pay dividends?

The dividend cannot currently be calculated for Astrazeneca Pharma India or the company does not pay out a dividend.

What is the Astrazeneca Pharma India ISIN?

The ISIN of Astrazeneca Pharma India is INE203A01020.

What is the Astrazeneca Pharma India ticker?

The ticker of Astrazeneca Pharma India is ASTRAZEN.NS.

How much dividend does Astrazeneca Pharma India pay?

Over the past 12 months, Astrazeneca Pharma India paid a dividend of 24 INR . This corresponds to a dividend yield of about 0.33 %. For the coming 12 months, Astrazeneca Pharma India is expected to pay a dividend of 24 INR.

What is the dividend yield of Astrazeneca Pharma India?

The current dividend yield of Astrazeneca Pharma India is 0.33 %.

When does Astrazeneca Pharma India pay dividends?

Astrazeneca Pharma India pays a quarterly dividend. This is distributed in the months of September, August, August, August.

How secure is the dividend of Astrazeneca Pharma India?

Astrazeneca Pharma India paid dividends every year for the past 6 years.

What is the dividend of Astrazeneca Pharma India?

For the upcoming 12 months, dividends amounting to 24 INR are expected. This corresponds to a dividend yield of 0.33 %.

In which sector is Astrazeneca Pharma India located?

Astrazeneca Pharma India is assigned to the 'Health' sector.

Wann musste ich die Aktien von Astrazeneca Pharma India kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Astrazeneca Pharma India from 9/6/2024 amounting to 24 INR, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did Astrazeneca Pharma India pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of Astrazeneca Pharma India in the year 2023?

In the year 2023, Astrazeneca Pharma India distributed 16 INR as dividends.

In which currency does Astrazeneca Pharma India pay out the dividend?

The dividends of Astrazeneca Pharma India are distributed in INR.

All fundamentals about Astrazeneca Pharma India

Our stock analysis for Astrazeneca Pharma India Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astrazeneca Pharma India Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.